Tetralogy of fallot prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
Maheep Sangha (talk | contribs)
No edit summary
 
(5 intermediate revisions by 4 users not shown)
Line 1: Line 1:
__NOTOC__
{{Tetralogy of fallot}}
{{Tetralogy of fallot}}


{{CMG}}; '''Associate Editors-In-Chief:''' [[Priyamvada Singh| Priyamvada Singh, M.B.B.S.]] [mailto:psingh@perfuse.org], [[User:KeriShafer|Keri Shafer, M.D.]] [mailto:kshafer@bidmc.harvard.edu];  '''Assistant Editor-In-Chief:''' [[Kristin Feeney|Kristin Feeney, B.S.]] [mailto:kfeeney@perfuse.org]
{{CMG}}; '''Associate Editors-In-Chief:''' [[Priyamvada Singh| Priyamvada Singh, M.B.B.S.]] [mailto:psingh13579@gmail.com], [[User:KeriShafer|Keri Shafer, M.D.]] [mailto:kshafer@bidmc.harvard.edu];  '''Assistant Editor-In-Chief:''' [[Kristin Feeney|Kristin Feeney, B.S.]] [mailto:kfeeney@elon.edu]
==Overview==
==Overview==
Factors that reduce [[systemic vascular resistance]] ([[SVR]]) may exacerbate shunting which in turn exacerbates cyanosis and should be avoided if at all possible in the patient with Tetralogy of Fallot.
Factors that reduce [[systemic vascular resistance]] ([[SVR]]) may exacerbate shunting which in turn exacerbates cyanosis and should be avoided if at all possible in the patient with Tetralogy of Fallot.
Line 8: Line 9:
No known prevention exists for Tetralogy of Fallot.
No known prevention exists for Tetralogy of Fallot.


==Prevention of Cyanosis==
===Prevention of Cyanosis===
The following factors may reduce [[systemic vascular resistance]] ([[SVR]]) and exacerbate shunting which in turn exacerbate cyanosis and should be avoided if at all possible:
The following factors may reduce [[systemic vascular resistance]] ([[SVR]]) and exacerbate shunting which in turn exacerbate cyanosis and should be avoided if at all possible:
:*[[Acidosis]]
*[[Acidosis]]
:*Bathing in hot water
*Bathing in hot water
:*[[Fever]]
*[[Fever]]
:*Stress
*Stress
:*Infection
*Infection
:*Posture (upright, not squatting)
*Posture (upright, not squatting)
:*Exercise
*Exercise
:*[[Beta-adrenergic agonists]]
*[[Beta-adrenergic agonists]]
:*[[Dehydration]]
*[[Dehydration]]
:*Closure of the [[patent ductus arteriosus]]
*Closure of the [[patent ductus arteriosus]]


==Prevention of Infective Endocarditis==
===Prevention of Infective Endocarditis===
*Antibiotic prophylaxis should be administered.
*Antibiotic prophylaxis should be administered.


==References==
==References==
{{Reflist|2}}
{{Reflist|2}}
==External links==
* [http://www.achaheart.org/resource/icon_cheartdefects_tdf.php Information for adults with ToF] from the Adult Congenital Heart Association
{{Congenital malformations and deformations of circulatory system}}
{{Electrocardiography}}
[[de:Fallot-Tetralogie]]
[[fr:Tétralogie de Fallot]]
[[it:Tetralogia di Fallot]]
[[nl:Tetralogie van Fallot]]
[[nn:Fallots tetrade]]
[[ja:ファロー四徴症]]
[[pl:Tetralogia Fallota]]
[[ru:Тетрада Фалло]]
[[uk:Тетрада Фалло]]
[[zh:法乐氏四联症]]


[[Category:Cardiology]]
[[Category:Cardiology]]
[[Category:Congenital heart disease]]
[[Category:Congenital heart disease]]
 
[[Category:Pediatrics]]
[[Category:Disease]]
{{WikiDoc Help Menu}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}

Latest revision as of 16:18, 5 March 2013

Tetralogy of fallot Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Tetalogy of Fallot from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural history, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Echocardiography

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

ACC/AHA Guidelines for Evaluation and Follow-up


Tetralogy of fallot prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Tetralogy of fallot prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Tetralogy of fallot prevention

CDC on Tetralogy of fallot prevention

Tetralogy of fallot prevention in the news

Blogs on Tetralogy of fallot prevention

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Tetralogy of fallot prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editors-In-Chief: Priyamvada Singh, M.B.B.S. [2], Keri Shafer, M.D. [3]; Assistant Editor-In-Chief: Kristin Feeney, B.S. [4]

Overview

Factors that reduce systemic vascular resistance (SVR) may exacerbate shunting which in turn exacerbates cyanosis and should be avoided if at all possible in the patient with Tetralogy of Fallot.

Prevention

No known prevention exists for Tetralogy of Fallot.

Prevention of Cyanosis

The following factors may reduce systemic vascular resistance (SVR) and exacerbate shunting which in turn exacerbate cyanosis and should be avoided if at all possible:

Prevention of Infective Endocarditis

  • Antibiotic prophylaxis should be administered.

References

Template:WikiDoc Sources